The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Progress has been made in HIV care. However, that doesn’t mean you don’t need a detailed plan for taking care of an ...

Gilead Sciences, the maker of a twice-a-year anti-HIV injection, has approached South Africa’s medicine regulator to discuss ...

Nomonde Ngema, 21, who was born with HIV, not only tackles the stigma on TikTok by sharing her journey, she also takes on ...

From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...

From an anal PrEP douche to the first women-controlled HIV prevention product, here's all the new HIV prevention products ...

The combination of tenofovir, FTC, and efavirenz might soon be available in a single pill. For years, effective antiretroviral treatment has required HIV-positive patients to take a large handful ...

Long-acting injectable PrEP is now to be covered without cost-sharing under Affordable Care Act rules, the Biden ...

The executive director of the organization says gender inequality is one of the most important drivers of new infections, ...

Gilead and Merck said their once-weekly pill to treat HIV resulted in a comparable level of viral suppression compared to a ...

The reasons to participate in the city’s annual AIDS Walk are as varied and diverse as the participants themselves. What is ...

A small French biotech is trumpeting results from a trial suggesting its developmental drug could be used as part of an HIV cure. The phase 2a trial of AbiVax’s ABX464 pill is small but confirms ...